Skip to main content

Drug Interactions between Anectine Flo-Pack and deflazacort

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

succinylcholine deflazacort

Applies to: Anectine Flo-Pack (succinylcholine) and deflazacort

MONITOR: The neuromuscular blocking effect of succinylcholine may be potentiated by chronic administration of estrogens or high-dose corticosteroids. Available data suggest that steroids may reduce plasma cholinesterase activity, resulting in decreased metabolic clearance of succinylcholine. There have been isolated case reports of patients treated with estrogen-containing products such as estradiol and diethylstilbestrol who experienced prolonged apnea or muscle paralysis following succinylcholine administration. Laboratory testing demonstrated reduced serum pseudocholinesterase activity in these patients. One study conducted in 33 women of childbearing age reported significantly reduced serum cholinesterase levels after one month of treatment with various oral contraceptives, with no further reductions after three months. Another 33 women in the same study who had been taking oral contraceptives for at least one year exhibited similarly reduced levels of serum cholinesterase.

MANAGEMENT: Patients receiving chronic therapy with estrogens or corticosteroids should be monitored for increased or prolonged neuromuscular blockade when succinylcholine is administered. A lower initial dosage of succinylcholine may be required.

References (4)
  1. (2022) "Product Information. Quelicin Chloride (succinylcholine)." Hospira Inc
  2. (2022) "Product Information. Anectine (succinylcholine)." Sandoz Inc
  3. (2022) "Product Information. Suxamethonium Chloride (suxamethonium)." Advanz Pharma
  4. (2021) "Product Information. Suxamethonium (Accord) (suxamethonium)." Accord Healthcare Pty Ltd, 1.0

Drug and food interactions

Moderate

deflazacort food

Applies to: deflazacort

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased systemic exposure to 21-desdeflazacort may increase the risk of corticosteroid adverse effects such as hypercorticism, hyperglycemia, adrenal suppression, immunosuppression, hypertension, salt and water retention, electrolyte abnormalities, behavioral and mood disturbances, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents.

MANAGEMENT: Deflazacort should not be administered with grapefruit juice.

References (1)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.